Ehtesham Ghani, MD
Internal Medicine · Brookfield, ILNPI 1316988397
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 24.7% of the total. 2025 is the largest year on record at $761, 2.1 times the $366 reported in 2019. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$922
- Lilly USA, LLC$543
- Boehringer Ingelheim$436
- Novo Nordisk$373
- Johnson & Johnson$260
- Pfizer$244
- plus $951 from 15 others
What the payments were for
- Food & beverage$3,729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $922 |
| Lilly USA, LLC | 23 | $543 |
| Boehringer Ingelheim | 19 | $436 |
| Novo Nordisk | 21 | $373 |
| Johnson & Johnson(2 entities) | 10 | $260 |
| Pfizer | 14 | $244 |
| Exact Sciences | 7 | $172 |
| Avanir Pharmaceuticals, Inc. | 7 | $128 |
| Phathom Pharmaceuticals, Inc. | 5 | $104 |
| E.r. Squibb & Sons, L.L.C. | 7 | $98 |
| Kowa Pharmaceuticals America, Inc. | 4 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| AbbVie(2 entities) | 3 | $64 |
| GSK | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Amgen | 2 | $38 |
| Circassia Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Mission Pharmacal Company | 1 | $15 |
| Linus Health, Inc. | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$126
How this compares
$3,729 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $53,254 |
| OzempicSemaglutide | 27 | $43,015 |
| JanuviaSitagliptin Phosphate | 25 | $26,612 |
| JardianceEmpagliflozin | 21 | $19,135 |
| EntrestoSacubitril/Valsartan | 11 | $7,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,884 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,975 |
| Febuxostat | 36 | $3,403 |
| Levothyroxine Sodium | 114 | $1,767 |
| Eplerenone | 12 | $1,711 |
| Pantoprazole Sodium | 98 | $937 |
| Metoprolol Succinate | 64 | $932 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $871 |
| Atorvastatin Calcium | 79 | $664 |
| Tamsulosin Hcl | 43 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $244 | $53,25466 claims |
| Novo NordiskOzempic | $373 | $43,01527 claims |
| Boehringer IngelheimJardiance | $436 | $19,13521 claims |
| NovartisEntresto | $17 | $7,37511 claims |
| GSKTrelegy Ellipta | $64 | $6,88411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Brookfield
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.